Drug Industry News
-
Pfizer Inc. and other drugmakers will avoid a reduction in U.S. government payments that was to be imposed in 2015 by a cost-cutting panel created by President Barack Obama’s Affordable Care Act.
-
Pharmaceutical companies will probably become more acquisitive this year as cash levels rise and financing remains inexpensive, and the size of deals is likely to increase, Moody’s Investors Service said.
-
Senate hearings, lawsuits and an Internal Revenue Service questionnaire are placing new scrutiny on nonprofit groups that spend millions of dollars on political campaigns without disclosing their donors.
-
Traders are betting that a bidding war for anti-aging cream maker Obagi Medical Products Inc. isn’t over yet.
-
In trying to get sophisticated medicines to its neediest citizens, India is increasingly pitting its generic-pharmaceutical industry against international drugmakers, threatening their growth in emerging markets.
-
India’s Supreme Court denied Novartis AG’s request for patent protection for its Gleevec cancer treatment, allowing the nation’s generic-drug makers to continue to sell copies of the drug at a lower price.
-
For more than a decade, drugmakers have battled U.S. Federal Trade Commission accusations that they have colluded to forestall the introduction of dozens of generic medicines, costing buyers as much as $3.5 billion a year.
-
U.S. Supreme Court justices suggested they will open drugmakers to suits over so-called pay- for-delay agreements, hinting at a ruling that would rewrite the rules governing the release of generic medicines.
-
House Republicans say a drugmaker- funded advertising campaign run by supposedly independent groups was part of an agreement with the Obama administration to help pass the U.S. health-care law in 2010.
-
Veeva Systems Inc. plans an initial public offering this year, people familiar with the matter said, stepping up a challenge to Oracle Corp. with Web-based software for pharmaceutical sales.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page